Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

The firm's chief scientific officer called the achievement "a major milestone for Spirovant and for the cystic fibrosis ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

Bayer on Tuesday struck a collaboration deal with U.S. biotech firm Cytokinetics to acquire certain rights in Japan to an experimental heart drug, as the German group strengthens its cardiovascular ...

The accused killers, 24-year-old Mike Vladislav Kruglik of West Bloomfield and 26-year-old Jesse Del Jordan Bradshaw of New ...

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

Midtown-based drug discovery company Schrodinger has entered a deal to advance multiple projects with pharmaceutical giant ...

Merck reported that a new formulation of Keytruda appears to deliver similar blood levels of the drug when given as a shot as ...

Amaury Abreu, 38, an 11-year NYPD veteran, had a secret life as the close confidant to the leader of a drug ring that ...

To combat the negative stigma of the treatment, the University of Arkansas for Medical Sciences (UAMS) Center for Addiction ...

Modifi Bio’s founders discuss the journey from developing a cancer treatment drug to being acquired by Big Pharma.

Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront ...